We serve Chemical Name:2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol CAS:14587-50-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol
CAS.NO:14587-50-9
Synonyms:Difeterol [INN];Pandryl;Difeterol (JAN/INN);Difeterol
Molecular Formula:C25H29NO2
Molecular Weight:375.50300
HS Code:2922509090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:517.2ºC at 760mmHg
Density:1.099g/cm3
Index of Refraction:1.587
PSA:32.70000
Exact Mass:375.22000
LogP:4.84650
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Difeterol [INN] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Difeterol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Difeterol (JAN/INN) Use and application,Difeterol technical grade,usp/ep/jp grade.
Related News: Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%. 2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol manufacturer The Environmental Working Group, a nonprofit advocacy organization, applauded the bill’s introduction. 2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol supplier The Environmental Working Group, a nonprofit advocacy organization, applauded the bill’s introduction. 2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol vendor The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful. 2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol factory The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful.